Trial Profile

A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WVE-003 (Primary)
Indications Huntington's disease
Focus Adverse reactions; First in man; Proof of concept
Acronyms SELECT-HD
Sponsors WaVe life Sciences

Most Recent Events

04 Mar 2025 According to a WaVe life Sciences media release, In February 2025, data from this study presented in an oral presentation at CHDI's 20th Annual HD Therapeutics Conference.
18 Jul 2024 Status changed from recruiting to completed.
25 Jun 2024 Results published in the WaVe life Sciences Media Release .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com